

1/20




Figure 1

BEST AVAILABLE COPY

2/20




Figure 2

3/20




Figure 3

4/20







Figure 4

5/20

A**B****Figure 5**


6/20

**Figure 6**


7/20

FIG 7**Primate $\gamma\delta$ cell number fold increase in response to increasing doses of Phosphostim**


5



8/20

FIG 8**Serum cytokine (INF γ and TNF α) production in Phosphostim treated primates**

9/20


FIG 9A

5



10/20

FIG9B

5



 $\gamma 9\delta 2$ T cells

11/20



FIG 10

BEST AVAILABLE COPY



12/20

FIG 11**BEST AVAILABLE COPY**

13/20

FIG 12**HDMAPP dose response : fold increase in absolute count****BrHPP dose response : fold increase in absolute count day 7****BEST AVAILABLE COPY**

14/20

FIG 13**HDMAPP dose response : fold increase in %gd****BrHPP dose response : fold increase in %gd day 7****BEST AVAILABLE COPY**

15/20

FIG 14A





FIG 14B



45

16/20

FIG 15
In vivo tumor development

5


10

786-O tumor

15

20

25




17/20

FIG 16

In vivo BrHPP stimulation and gdT cell proliferation

5




BEST AVAILABLE COPY

18/20

FIG 17

In vivo BrHPP stimulation and gdT cell proliferation




5

BEST AVAILABLE COPY

FIG 18
Long-term anti-tumoral activity

5



20/20

FIG 19
Gamma delta anti-tumoral activity

